Riskpilot← Back to searchSign inGet full accessHemoCue Aktiebolag
ABActiveOrg 5563429272Kuvettgatan 1Manufacture of instruments and appliances for measuring, testing and navigation · NACE 2651Est. 1988271 employees
Revenue 2024
SEK 840,4M
+6% vs 2023
EBITDA margin
28.6%
+14% vs 2023
Equity ratio
28.5%
Financial strength
Net profit 2024
SEK 167,2M
+9% vs 2023
| Revenue | SEK 840,4M | +6% |
| EBITDA | SEK 240M | +14% |
| Net profit | SEK 167,2M | +9% |
| Total assets | SEK 824,8M | +5% |
| Equity | SEK 235,1M | +8% |
| Employees | 271 | — |
Legal name
HemoCue Aktiebolag
Org number
5563429272
Legal form
Aktiebolag
NACE code
2651 · Manufacture of instruments and appliances for measuring, testing and navigation
Founded
1 december 1988
Share capital
SEK 25 200 000
Employees
271 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Schweitz, Kasper Oktavio i förening med en av Hammerschmidt-Broman, Melanie van Parys, Francis Albert L. Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall självt eller genom dotterbolag bedriva utveckling, tillverkning, marknadsföring och försäljning av utrustning och metoder för diagnostik, främst inriktad på sjuk- och hälsovård, och att äga och/eller inneha nyttjanderätt till patent och upplåta licenser och underlicenser, och att äga och förvalta aktier, andelar och värdepapper ävensom idka därmed förenlig verksamhet.
Address
Kuvettgatan 1
Phone
+46431481200
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 592 661 | 631 040 | 686 780 | 789 154 | 840 363 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 176 812 | 179 002 | 173 356 | 210 040 | 240 008 |
| Depreciation & amort. | −12 137 | −8 158 | −8 349 | −9 314 | −15 840 |
| EBIT | 164 675 | 170 844 | 165 007 | 200 726 | 224 168 |
| Net financials | −4 529 | −5 116 | −8 338 | −2 949 | 9 942 |
| Profit before tax | −4 146 | 5 340 | 64 165 | 195 999 | 213 191 |
| Tax | 756 | −1 605 | −13 919 | −42 077 | −45 985 |
| Net profit | −3 390 | 3 735 | 50 246 | 153 922 | 167 206 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 894 606 | 1 090 509 | 757 679 | 788 870 | 824 827 |
| Equity | 484 982 | 488 717 | 138 963 | 217 886 | 235 092 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 103 483 | 301 186 | 308 319 | 236 226 | 220 640 |
| Total debt | 103 483 | 301 186 | 308 319 | 236 226 | 220 640 |
EBITDA margin
28.6%
This company
15.8%
Market median
+81% vs market
20202024
Equity ratio
28.5%
This company
38.2%
Market median
-25% vs market
20202024
Return on equity
71.1%
This company
18.4%
Market median
+286% vs market
20202024
Net profit margin
19.9%
This company
8.1%
Market median
+146% vs market
20202024
Asset turnover
1.02×
This company
1.12×
Market median
+9% vs market
20202024
Debt / equity
2.51×
This company
0.62×
Market median
-305% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
KO Chief Executive Officer | Chief Executive Officer | 2020 |
LJ Chief Auditor | Chief Auditor | 2020 |
| Former (3) | ||
AH External Signatory | External Signatory | 2020 – 2022 |
MH External Signatory | External Signatory | 2020 – 2024 |
SP External Signatory | External Signatory | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2024 | |
| Chairman | 2024 | |
| Board of Directors | 2025 | |
| Board of Directors | 2024 | |
| Former (7) | ||
| Board of Directors | 2020 – 2025 | |
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2022 – 2024 | |
| Board of Directors | 2020 – 2024 | |
| Chairman | 2020 – 2024 | |
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HCAB US HOLDING LLCHC Holding Sweden AB
HemoCue Aktiebolag (this company)Hemocue South Africa (Pty) LtdHEMOCUE SOUTH AFRICA (PTY) LTDHemocue (Suzhou) Medical Technology Co.LtdHEMOCUE (SUZHOU) MEDICAL TECHNOLOGY CO.LTDBoard members of HemoCue Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kasper Oktavio Schweitz | Chief Executive Officer | 0 companies |
| Andreas Hans Ekberg | External Signatory | 0 companies |
| Lars Johan Peter Gunnarsson | Chief Auditor | 0 companies |
| Marianne Helstrup | External Signatory | 0 companies |
| Sofie Petra Linnéa Ljungheimer | External Signatory | 0 companies |
| Oscar Fredric Alexander Lindberg | Board of Directors | 0 companies |
| Per Henrik Pommer | Deputy Board Member | 0 companies |
| Lars Robert Harr | Board of Directors | 0 companies |
| Björn Åke Mikael Bylander | Deputy Board Member | 0 companies |
| Francis Albert L. van Parys | Chairman | 0 companies |
| Hans Christian Olsson | Board of Directors | 0 companies |
| Claus Lønborg Madsen | Board of Directors | 0 companies |
| Henrik Schimmell Nielsen | Chairman | 0 companies |
| Melanie Hammerschmidt-Broman | Board of Directors | 0 companies |
| Katarina Elisabet Cooper | Board of Directors | 0 companies |
| Jan Mikael Rune Godolakis | Deputy Board Member | 0 companies |